🟢 Taysha Gene Therapies is trading 6.84% up today with no confirmed company-specific catalyst

Taysha Gene Therapies is trading 6.84% higher at $3.75, with no confirmed new company-specific announcement identified for October 15.

• Previously announced encore presentations of TSHA-102 Rett syndrome trial results are scheduled at the Child Neurology Society meeting, including an October 15 oral presentation; the results had been presented earlier.
• The biotech sector advanced 2.20%, offering a plausible supportive backdrop but not establishing the precise cause of the stock’s move.